Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B London

Showing results (251-260 of 310) with videos related to

Pageof 31
Sort By:
Cancer Research|May 20, 2016
MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of DyskerinRosemary O'Brien, Sieu L Tran, Michelle F Maritz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2020
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology GroupRajen Mody, Alice L Yu, Arlene Naranjo, et al.
Journal for Immunotherapy of Cancer|February 23, 2023
KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology GroupAmy K Erbe, Mitch B Diccianni, Rajen Mody, et al.
Nature|October 17, 2008
Activating mutations in ALK provide a therapeutic target in neuroblastomaRani E George, Takaomi Sanda, Megan Hanna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II studySuzanne Shusterman, Wendy B London, Stephen D Gillies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2021
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032Alice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, et al.
Pediatric Blood & Cancer|April 11, 2019
Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 studySteve E Braunstein, Wendy B London, Susan G Kreissman, et al.
JAMA Oncology|January 30, 2016
Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) StudyMarian H Harris, Steven G DuBois, Julia L Glade Bender, et al.
Frontiers in Immunology|June 30, 2017
HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer ImmunotherapyAmy K Erbe, Wei Wang, Patrick K Reville, et al.
Cancer Research|December 3, 2008
ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastomaMichael D Hogarty, Murray D Norris, Kimberly Davis, et al.
Pageof 31

Showing results (251-260 of 310) with videos related to

Sort By:
Pageof 31
Cancer Research|May 20, 2016
MYC-Driven Neuroblastomas Are Addicted to a Telomerase-Independent Function of DyskerinRosemary O'Brien, Sieu L Tran, Michelle F Maritz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2020
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology GroupRajen Mody, Alice L Yu, Arlene Naranjo, et al.
Journal for Immunotherapy of Cancer|February 23, 2023
KIR/KIR-ligand genotypes and clinical outcomes following chemoimmunotherapy in patients with relapsed or refractory neuroblastoma: a report from the Children's Oncology GroupAmy K Erbe, Mitch B Diccianni, Rajen Mody, et al.
Nature|October 17, 2008
Activating mutations in ALK provide a therapeutic target in neuroblastomaRani E George, Takaomi Sanda, Megan Hanna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II studySuzanne Shusterman, Wendy B London, Stephen D Gillies, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 28, 2021
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032Alice L Yu, Andrew L Gilman, M Fevzi Ozkaynak, et al.
Pediatric Blood & Cancer|April 11, 2019
Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 studySteve E Braunstein, Wendy B London, Susan G Kreissman, et al.
JAMA Oncology|January 30, 2016
Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) StudyMarian H Harris, Steven G DuBois, Julia L Glade Bender, et al.
Frontiers in Immunology|June 30, 2017
HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer ImmunotherapyAmy K Erbe, Wei Wang, Patrick K Reville, et al.
Cancer Research|December 3, 2008
ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastomaMichael D Hogarty, Murray D Norris, Kimberly Davis, et al.
Pageof 31